Tau Biomarkers in Late-onset Psychosis (LOP)

Last updated: March 27, 2024
Sponsor: Jeremy Koppel
Overall Status: Active - Recruiting

Phase

N/A

Condition

Psychosis

Mood Disorders

Tourette's Syndrome

Treatment

Tau PET imaging scan

Clinical Study ID

NCT06336382
23-0874
1R21MH135148
  • Ages 65-85
  • All Genders

Study Summary

Hallucinations or delusions that occur for the first time in older people with no acute medical problems or mood symptoms may be related to impending dementia. This study aims to confirm this hypothesis using novel blood biomarkers and Positron Emission Tomography (PET) imaging tracers, as well as non-invasive testing.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Male or female, aged 65-85 years.
  2. Diagnosis of late-onset non-affective primary psychotic disorder consistent witheither very late-onset schizophrenia-like psychosis (VLOSP, International Late-OnsetSchizophrenia Group consensus criteria, Howard et al., 2000) or delusional disorder (DSM-5 criteria)
  3. Caregiver available to provide collateral history and participation in informant-basedratings (NPI,CDR)
  4. Clinical Dementia Rating (CDR) score of 0 or 0.5.
  5. Mini-Mental State Examination (MMSE) score ≥ 24 and at the screening visit.
  6. Normal memory function (to rule-out mild cognitive impairment, MCI) documented byscoring within 1.5 SD range in education adjusted norms of the Logical Memory IIsubscale
  7. Ability to hear 500, 1000 and 1500 Hz bilaterally on a hearing evaluation (hearingaids permitted).

Exclusion

Exclusion Criteria:

  1. Participants with affective and psychotic disorders including bipolar disorder,schizoaffective disorder, active major depression; insulin dependent type 2 diabetes;a history of CVD; a history of epilepsy; a history of TBI with greater than 15 minutesof loss of consciousness; a movement disorder including Parkinson's disease; stroke;autoimmune disease affecting the CNS; substance abuse disorder; or activedelirium/encephalopathy.
  2. Evidence of a clinically relevant neurological disorder
  3. Modified Hachinski ischemia score of more than 4.
  4. History of alcoholism or drug dependency/abuse within the last 5 years beforescreening.
  5. Presence of metal implants such as pacemakers, ear implants, internal bullet fragmentsor shrapnel.
  6. Inability to lie flat for 1 hour approximately.
  7. Hearing impairment as evidenced by the inability to hear 500, 1000 and 1500 Hzbilaterally on a hearing evaluation. Subjects with hearing aids will be allowed toparticipate if they meet minimum hearing requirements.

Study Design

Total Participants: 16
Treatment Group(s): 1
Primary Treatment: Tau PET imaging scan
Phase:
Study Start date:
February 16, 2024
Estimated Completion Date:
June 30, 2027

Study Description

Psychotic symptoms that occur in advanced age in the absence of an acute medical condition or prominent mood symptoms can represent the late appearance of primary psychotic disorders such as very late-onset schizophrenia-like psychosis (VLOSP) or delusional disorder, or can presage the appearance of a neurodegenerative condition such as Alzheimer's disease (AD). An episode of non-affective psychosis late in life more than doubles the risk of subsequent neurodegenerative disease, with an average time from psychosis to AD diagnosis of 18 months. The biologic mechanisms responsible for the increased risk of dementia in those who experience psychosis are unclear. One hypothesis is reverse causality, in which inchoate neurodegeneration is responsible for psychotic symptoms that emerge in the absence of traditional cognitive hallmarks of dementia. The psychosis then heralds the inception of illness that will eventuate in cognitive decline. The investigators will utilize neurodegenerative biomarkers in the form of novel PET imaging tracers, plasma immunoassays and non-invasive neurophysiologic measurements to test this hypothesis in a pilot cohort of elderly subjects suffering with psychosis occurring in late-life without dementia for comparison with a cohort of healthy elderly controls (HEC)s who are participating in a study focused on those with dementia.

Connect with a study center

  • The Feinstein Institutes for Medical Research

    Manhasset, New York 11030
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.